BioSpace News Archive

Enlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences Group

Enlaza Therapeutics on Tuesday announced financing led by the Life Sciences Group of J.P. Morgan Asset Management’s Private Capital division, which the California-based company will use to build its pipeline of covalent biologics.

April 30, 2024
·
2 min read
·
Kate Goodwin
FDA

Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer

Based on strong overall and progression-free survival data in its Phase III confirmatory study, Pfizer and Genmab’s antibody-drug conjugate Tivdak on Monday secured the FDA’s full approval for recurrent or metastatic cervical cancer that had progressed on or after chemotherapy.

April 30, 2024
·
2 min read
·
Tristan Manalac
Business

Lilly Touts 26% Q1 Revenue Growth on Strong Mounjaro Sales, Raises Full-Year Guidance by $2B

Thanks to strong sales of its blockbuster drugs Mounjaro and Zepbound, Eli Lilly on Tuesday reported nearly $8.77 billion in revenue in the first quarter of 2024, while raising its full-year revenue guidance by $2 billion.

April 30, 2024
·
2 min read
·
Tristan Manalac
Drug Development

AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu significantly improved progression-free survival in metastatic breast patients with low and ultralow HER2 expression levels who had received at least one line of systemic treatment.

April 30, 2024
·
2 min read
·
Tristan Manalac
Policy

J&J, BMS Lose Challenges to Medicare Drug Price Negotiation Program

A federal court issued a summary judgment saying that the IRA provision does not represent an unconstitutional taking of property but did not rule on suits by Novartis and Novo Nordisk.

April 30, 2024
·
2 min read
·
Neil Versel
Business

Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership

Under the latest teaming between the two companies, who have worked together since 2010, Novartis will pay $180 million upfront to PeptiDream to find new radioligand therapies.

April 30, 2024
·
2 min read
·
Tyler Patchen
Drug Development

Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique

The FDA has cleared a clinical trial of an ex vivo prime editing candidate in patients with a rare disease, Prime Medicine announced Monday. The technique taps CRISPR technology to rewrite defective genes without breaking DNA double helix strands.

April 30, 2024
·
2 min read
·
Nick Paul Taylor
Policy

Drug Companies, VCs Rethink R&D Strategies as IRA Stands Strong in Court

This week’s legal losses by J&J and BMS reinforce the notion that Medicare drug price negotiation is here to stay, and investors continue to favor biologics over small molecules.

April 30, 2024
·
6 min read
·
Neil Versel
Business

Relief Therapeutics has Published its Annual Report

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, published its Annual Report 2023 and provided a corporate update.

April 30, 2024
·
2 min read
Deals

Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate

Poolbeg Pharma announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel topical muco-adherent formulation of Pentoxifylline for the treatment of oral ulcers in patient’s suffering from Behçet’s Disease.

April 30, 2024
·
8 min read